Cadrenal Therapeutics' Board has authorized a formal strategic review to evaluate opportunities for maximizing shareholder value, including potential licensing deals, asset sales, partnerships, or business combinations. The company engaged Tungsten Advisors as exclusive financial advisor. This move follows strong interest from partners and recent FDA alignment on the Phase 3 pathway for its lead candidate CAD-1005. Cadrenal Therapeutics is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions.
